Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cellular Senescence: Aging, Cancer, and Injury.

Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A.

Physiol Rev. 2019 Apr 1;99(2):1047-1078. doi: 10.1152/physrev.00020.2018. Review.

PMID:
30648461
2.

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M.

Nat Commun. 2018 Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.

3.

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A.

Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27.

4.

Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression.

Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Bicciato S, Doglioni C, Bellone M, Casorati G, Dellabona P.

Cell Rep. 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058.

5.

Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer.

Calcinotto A, Alimonti A.

Swiss Med Wkly. 2017 Jan 17;147:w14367. doi: 10.4414/smw.2017.14367. eCollection 2017.

6.

IAP antagonists induce anti-tumor immunity in multiple myeloma.

Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL.

Nat Med. 2016 Dec;22(12):1411-1420. doi: 10.1038/nm.4229. Epub 2016 Nov 14.

7.

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. Epub 2016 Sep 12. No abstract available.

PMID:
27619513
8.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

9.

Targeting vasculogenesis to prevent progression in multiple myeloma.

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM.

Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.

PMID:
26859080
10.

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M.

Oncoimmunology. 2015 May 7;4(6):e1008850. eCollection 2015 Jun.

11.

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.

Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, Calcinotto A, Freschi M, Bachi A, Galli R, Bellone M.

Cancer Res. 2015 May 15;75(10):2095-108. doi: 10.1158/0008-5472.CAN-14-2346. Epub 2015 Mar 25.

12.

Boosting anticancer vaccines: Too much of a good thing?

Ricupito A, Grioni M, Calcinotto A, Bellone M.

Oncoimmunology. 2013 Jul 1;2(7):e25032. Epub 2013 May 16.

13.

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes.

Bellone M, Calcinotto A.

Front Oncol. 2013 Sep 11;3:231. doi: 10.3389/fonc.2013.00231. Review.

14.

Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.

Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, Freschi M, Mondino A, Galli R, Bellone M.

Oncoimmunology. 2013 May 1;2(5):e24520. Epub 2013 Apr 16.

15.

Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.

Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M.

Cancer Res. 2013 Jun 15;73(12):3545-54. doi: 10.1158/0008-5472.CAN-12-2449. Epub 2013 Mar 28.

16.

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors.

Bellone M, Calcinotto A, Filipazzi P, De Milito A, Fais S, Rivoltini L.

Oncoimmunology. 2013 Jan 1;2(1):e22058.

17.

Won't you come on in? How to favor lymphocyte infiltration in tumors.

Bellone M, Calcinotto A, Corti A.

Oncoimmunology. 2012 Sep 1;1(6):986-988.

18.

Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L.

Cancer Res. 2012 Jun 1;72(11):2746-56. doi: 10.1158/0008-5472.CAN-11-1272. Epub 2012 May 16.

19.

Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.

Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M.

J Immunol. 2012 Mar 15;188(6):2687-94. doi: 10.4049/jimmunol.1101877. Epub 2012 Feb 8.

20.

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E; NIBIT, Parmiani G.

Cancer Immunol Immunother. 2011 Jun;60(6):901-7. doi: 10.1007/s00262-011-1006-6. Epub 2011 Mar 24. No abstract available.

PMID:
21431916

Supplemental Content

Loading ...
Support Center